Ocutrx Vision Technologies Names Dr. Linda Lam as Chief Scientific and Strategy Officer


IRVINE, Calif.—Ocutrx Vision Technologies, a California-based developer of augmented reality (AR) glasses, has named Dr. Linda Lam, MD, MBA, to the company’s executive management team in the role of chief scientific and strategy officer. Currently an associate professor of ophthalmology and vice chair of Satellite Clinical Affairs at the USC Keck School of Medicine, Dr. Lam will lead the development and oversight of the scientific, technological and research operations currently underway at Ocutrx, according to an announcement last week.

In this position, she will guide new technology development as well as help align current and future R&D efforts with organizational priorities, industry trends and growth opportunities.

"We are pleased to welcome Dr. Lam into the management team at Ocutrx,” said Michael H. Freeman, chief executive officer and chief technology officer at the company. “Dr. Lam has a track record as an outstanding clinician, innovator and educator. Her commitment to innovation, scholarly research and improved patient outcomes is an excellent fit with Ocutrx’s flagship product, the Oculenz augmented reality glasses for low vision patients among other applications. We are confident the leadership for science and strategy is being placed into very experienced and capable hands."

Dr. Lam brings a deep expertise in complex medical and surgical vitreoretinal cases to Ocutrx. Her unique skill set also extends to clinical operations and strategy, research in macular degeneration, medical devices, artificial intelligence research and vision rehabilitation, according to the announcement. In addition to her work at the USC Keck School of Medicine, Dr. Lam is also an executive board member of the Braille Institute of America and member of the board of low vision rehabilitation for the American Academy of Ophthalmology.

“The work Ocutrx is doing to advance augmented reality products and broader medical technology in the augmented reality space is revolutionary and broadly applicable across multiple demographics, industries and levels of visual impairments,” Dr. Lam said in the announcement. “I’m thrilled with the opportunity to contribute to the groundbreaking work at Ocutrx and I can’t wait to share with the medical community some of the exciting progress we have in store for 2019.”